Short interest for Lode Gold Resources gives investors a sense of the degree to which investors are betting on the decline of Lode Gold Resources's stock. Short interest data is updated every two weeks.

Lode Gold Resources Stock (OTC:SBMIF), Short Interest Report

Lode Gold Resources Inc is a Canadian exploration and development company with grassroots and advanced exploration properties in highly prospective and safe mining jurisdictions. The company projects are McIntyre Brook Project, Golden Culvert and Win Projects. It also holds a pipeline of early-stage exploration projects including the critical mineral Captain Cobalt-Copper-Gold Deposit in New Brunswick and the Dingman Gold Project, Ontario.

LODE GOLD RESOURCES INC. by Lode Gold Resources Inc.

Lode Gold Resources Inc

News

AREB

American Rebel Signs Distribution Agreement With Bonbright Distributors For Nine Counties In The Dayton, Ohio Area

Roth MKM analyst George Kelly upgrades Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) from Neutral to Buy and raises the price target from $1.3 to $4.5.

Upgrades

Price Target

Analyst Ratings

Roth MKM Upgrades Laird Superfood to Buy, Raises Price Target to $4.5

Saga Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGA#NASDAQ">SGA</a>) reported quarterly losses of $(0.25) per share. This is a 266.67 percent decrease over earnings of $0.15 per share from the same period last year. The company reported $24.66 million in sales this quarter. This is a 2.53 percent decrease over sales of $25.30 million the same period last year.

Earnings

Saga Communications  Q1 EPS GAAP $(0.25) Down From $0.15 YoY, Sales $24.66M Down From $25.30M YoY

Interlink Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINK#NASDAQ">LINK</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $3.124 million which missed the analyst consensus estimate of $3.344 million by 6.58 percent. This is a 4.70 percent decrease over sales of $3.278 million the same period last year.

Earnings Misses

LINK

Interlink Electronics Q1 2024 GAAP EPS $(0.09) Misses $(0.07) Estimate, Sales $3.124M Miss $3.344M Estimate

Beyond Meat, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) shares are trading lower in the premarket session on Thursday after ending yesterday&#8217;s run<a target="_blank" href="https://www.benzinga.com/news/earnings/24/05/38715054/beyond-meat-q1-earnings-revenue-beat-eps-miss-working-to-make-2024-a-pivotal-year-and-more" rel="noreferrer noopener">&nbsp;with a mild 0.9% dip.</a>
On Wednesday, after the closing bell, the company reported&nbsp;first-quarter financial results,&nbsp;where&nbsp;President and CEO&nbsp;Ethan Brown&nbsp;emphasized the company&#8217;s dedication&nbsp;for&nbsp;achieving sustainable and profitable operations.
The&nbsp;plant-based meat&nbsp;company&#8217;s first-quarter revenue decreased 18% year-over-year to $75.603 million.&nbsp;
In the wake of a surge in inflation, consumers are showing reduced inclination to fork out extra for plant-based protein products in the post-pandemic era, Forbes&nbsp;<a target="_blank" href="https://www.forbes.com/sites/greatspeculations/2024/05/08/down-8-this-year-will-beyond-meat-stock-recover-following-q1-results/?sh=7d1b6d24af69" rel="noreferrer noopener">reported</a>. Over the past three years, the company has grappled with dwindling revenue and substantial cash outflow.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BYND stock has slumped over 30% in the past year.&nbsp;
In the&nbsp;recently-reported&nbsp;first quarter, the company&#8217;s gross profit decreased to $3.7 million from $6.2 million in the year-ago period. The company&#8217;s gross margin contracted to 4.9% from 6.7% year over year.
The margins were negatively impacted by the lower volume of products sold and&nbsp;by&nbsp;higher manufacturing costs, including depreciation,&nbsp;higher&nbsp;materials costs, and lower net revenues per pound.
Adjusted EBITDA was a&nbsp;loss of&nbsp;$(32.9) million, or -43.5% of net revenues, in the first quarter of 2024.
Beyond Meat exited the quarter with cash and equivalents worth $173.5 million&nbsp;and&nbsp;total&nbsp;outstanding debt&nbsp;was&nbsp;$1.1 billion as of March 30.
Beyond Meat expects second-quarter revenue to be between $85 million and $90 million. The company expects full-year 2024 revenue to be between $315 million and $345 million.
Price Action: BYND shares are trading lower by 14.67% to $7.01 premarket at last check Thursday.
Photo via Shutterstock

Equities

Markets

Movers

General

BYND

What's Going On With Beyond Meat Shares Thursday?

Wedbush analyst Robert Driscoll upgrades CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) from Neutral to Outperform and raises the price target from $3 to $8.

CTMX

Wedbush Upgrades CytomX Therapeutics to Outperform, Raises Price Target to $8

Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly earnings of $0.66 per share. This is a 186.84 percent increase over losses of $(0.76) per share from the same period last year. The company reported $7.50 million in sales this quarter. This is a 13.54K percent increase over sales of $54.99 thousand the same period last year.

LPCN

Lipocine Q1 EPS $0.66 Up From $(0.76) YoY, Sales $7.50M Up From $54.99K YoY

INTR

Inter&Co Q1 Revenue R$2.3B Up 27% YoY

Wedbush analyst Jay McCanless reiterates Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) with a Outperform and maintains $13 price target.

Reiteration

RITM

Wedbush Reiterates Outperform on Rithm Capital, Maintains $13 Price Target

ACEN Australia and Energy Vault to collaborate on battery energy storage system (BESS) deployments, with 200 MW/400 MWh system, at ACEN Australia's 720 MW New England Solar
The 50 MW/100 MWh and 150 MW/300 MWh New England Solar BESS deployments will begin construction in the second half of 2024 with the start of commercial operations expected in 2025
Agreement with one of Australia's largest renewable energy producers represents execution of Energy Vault's long term strategy and investment commitments to energy storage for the Australian market
Energy Vault Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) ("Energy Vault"), a leader in sustainable, grid-scale energy storage solutions, and ACEN Australia, today announced the main contractual agreements for two battery energy storage system (BESS) deployments totaling 400 MWh in Australia. Construction on both deployments is expected to begin in the second half of 2024, with commercial operations expected in 2025 and 2026. The agreements are under final contract procedural preparation, and expected to be executed and closed formally within the first half of May 2024.
Under the agreement, Energy Vault will deploy both a 50 MW/100 MWh BESS and a 150 MW/300 MWh BESS at ACEN Australia's 720 MW New England Solar, one of the largest solar projects to participate in Australia's National Electricity Market (NEM). The BESS will be charged and discharged on a daily basis and designed to dispatch stored renewable energy at peak consumption hours to help meet the high demand during New South Wales' peak load hours while reducing the region's reliance on coal-fired power generation. Currently supported by the NSW Government's Emerging Energy Program, the New England BESS project is a part of ACEN's broader strategy in Australia, where they are actively developing over 1 GW of projects.

Contracts

NRGV

Energy Vault, ACEN Australia Announce Agreement For 400 MWh Of Battery Energy Storage Deployments

VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 89.86 percent increase over losses of $(1.48) per share from the same period last year. The company reported quarterly sales of $98.00 thousand which missed the analyst consensus estimate of $100.00 thousand by 2.00 percent. This is a 1.01 percent decrease over sales of $99.00 thousand the same period last year.

Earnings Beats

VYNE

VYNE Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate, Sales $98.00K Miss $100.00K Estimate

Wedbush analyst Jay McCanless reiterates CoreCivic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) with a Outperform and maintains $19 price target.

Wedbush Reiterates Outperform on CoreCivic, Maintains $19 Price Target

Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.36) per share from the same period last year.

EWTX

Edgewise Therapeutics Q1 EPS $(0.33) Beats $(0.39) Estimate

Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.00) by 9 percent. This is a 9.17 percent increase over losses of $(1.20) per share from the same period last year.

IRON

Disc Medicine Q1 EPS $(1.09) Misses $(1.00) Estimate

Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.04 by 1350 percent. The company reported quarterly sales of $111.800 million which beat the analyst consensus estimate of $102.574 million by 8.99 percent. This is a 162.77 percent increase over sales of $42.546 million the same period last year.

CLSK

Cleanspark Q2 2024 GAAP EPS $0.58 Beats $0.04 Estimate, Sales $111.800M Beat $102.574M Estimate

Warner Bros. Discovery, Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)&nbsp;reported a fiscal first-quarter revenue decline of 7% ex-FX year-on-year to $9.96 billion, missing the consensus of&nbsp;<a target="_blank" href="https://ir.wbd.com/investor-relations/default.aspx" rel="noreferrer noopener">$10.23 billion</a>.&nbsp;
EPS loss of $(0.40) missed the&nbsp;consensus loss of $(0.23). Net loss was $(966) million versus $(1.07) billion year-over-year.
The company reported an adjusted EBITDA of $2.10 billion, a 20% ex-FX decline, primarily driven by the success of Hogwarts Legacy in the prior year quarter, while&nbsp;Suicide Squad: Kill the Justice League generated significantly lower revenues.
Studios&nbsp;revenues&nbsp;were $2.82 billion, down 13% ex-FX Y/Y on a pro forma combined basis. Content revenue decreased 14% due to the impact of the WGA and SAG-AFTRA strikes and specific large licensing deals in the prior&nbsp;year.&nbsp;
Networks&nbsp;revenues&nbsp;were $5.13 billion, down by 8% ex-FX, on a pro forma combined basis.&nbsp; The AT&amp;T SportsNet exit negatively impacted the growth rate by 200 bps.
Distribution revenue decreased 6% ex-FX, primarily driven by declines in U.S. pay-TV subscribers.&nbsp;
Advertising revenue fell 11% ex-FX, primarily driven by audience declines in domestic general entertainment and news networks and soft advertising markets, mainly in the U.S.&nbsp; and Latin America.
DTC revenues&nbsp;were $2.46 billion, flat ex-FX Y/Y on a pro forma combined basis. Distribution revenue increased by 1% ex-FX, primarily attributable to price increases in the U.S., Latin America, and specific international markets.
Advertising revenue increased 70% ex-FX, primarily driven by higher engagement on Max in the U.S.
Total DTC subscribers increased to 99.6 million from 98.5 million a year ago. Global DTC ARPU was $7.83, a 4% ex-FX increase from the prior year.
WBD generated $585 million in operating cash flow and held $3.4 billion in cash and equivalents as of March 31, 2024.&nbsp;
WBD&#8217;s earnings follow the company&#8217;s plans to bundle its streaming services&nbsp;with those of&nbsp;Walt Disney Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), binding Max, Disney+, and Hulu and offering&nbsp;it&nbsp;to consumers this summer at a discount, CNBC&nbsp;<a target="_blank" href="https://www.cnbc.com/2024/05/09/warner-bros-discovery-wbd-earnings-q1-2024.html" rel="noreferrer noopener">reports</a>.
Price Action: WBD shares traded lower by 2.18% at $7.63 premarket at the last check Thursday.

Tech

Media

Warner Bros. Discovery's Q1 Revenue Drops as Audience and Market Challenges Persist

First Quarter Financial Results
<ul>
<li>Cash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily driven by the proceeds of the follow-on offering and warrant exercises partially offset by cash outflows related to research and development costs as the Company continues development of obicetrapib and increased spending on selling, general and administrative expenses to support the Company's growing organization.</li>
<li>Revenue: NewAmsterdam recognized $1.4 million in revenue for the quarter ended March 31, 2024, compared to $8.6 million in the same period in 2023. This decrease was primarily due to the recognition of license revenue related to a clinical development milestone in the quarter ended March 31, 2023 while no clinical development milestones were achieved in the same period in 2024.</li>
<li>Research and Development ("R&amp;D") Expenses: R&amp;D expenses were $42.4 million in the quarter ended March 31, 2024, compared to $40.4 million for the same period in 2023. This increase was primarily due to an increase in clinical expenses related to the Company's ongoing Phase 3 clinical trials, partially offset by a decrease in manufacturing costs.</li>
<li>Selling, General and Administrative ("SG&amp;A") Expenses: SG&amp;A expenses were $14.5 million in the quarter ended March 31, 2024, compared to $8.1 million for the same period in 2023. This increase was primarily due to an increase in personnel costs related to expansion of the team to support the growth of the organization and investments in capabilities to support the Company's planned commercial launch of obicetrapib, if approved.</li>
<li>Net loss: Net loss for the quarter ended March 31, 2024 was $93.8 million, or $1.06 per diluted share, compared to net loss of $42.0 million, or $0.51 per diluted share, for the same period in 2023.</li>
</ul>

NAMS

NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0.51) YoY

Telsey Advisory Group analyst Dana Telsey maintains Clear Secure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) with a Outperform and maintains $34 price target.

Telsey Advisory Group Maintains Outperform on Clear Secure, Maintains $34 Price Target

CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) reported quarterly losses of $(0.36) per share. This is a 88.82 percent increase over losses of $(3.22) per share from the same period last year.

CGON

CG Oncology Q1 EPS $(0.36) Up From $(3.22) YoY

Goldman Sachs analyst Bonnie Herzog maintains Zevia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZVIA#NYSE">ZVIA</a>) with a Neutral and lowers the price target from $3 to $1.25.